Clinical Program Lead
Boehringer Ingelheim International GmbH, Germany
Mehdi Lahmar joined Boehringer Ingelheim in Germany as a Clinical Program Lead in Oncology in November 2019 and is currently Evidence Lead for the MDM2-p53 antagonist program at BI. He was previously Head of Project Development in a Paris-based biotech company, Gamamabs, where he was responsible for advancing the company’s pipeline, coordinating the preclinical and clinical stage candidates in immune-oncology as well as interfacing with number of external stakeholders. He contributed to the advancement of drug candidates from Phase I to later stages of development.
Prior to Gamamabs, Mehdi worked as project and team lead for number of drug development programs (monoclonal antibodies, small molecules and vaccines) in different therapeutic areas (infectious diseases, immunology and oncology) at Vivalis SA and Valneva SE; leading multinational teams across all functions.
He received his PhD in Biotechnological Therapeutics from Paris Diderot (Paris7) University in 2008 and his Medical Degree (Obstetrics Gynaecology Oncology) from Tunis Medical School in 2003 and trained in number of French Hospitals among which the European Hospital George Pompidou (Department of oncological surgery) and Tenon Hospital in Paris (Department of obstetrics, gynaecology and oncology).